Merck's Investigational Two-Drug Regime For HIV Meets Primary Goal In Two Late-Stage Trials

Zinger Key Points

On Thursday, Merck & Co Inc MRK revealed topline results from two pivotal Phase 3 trials of a two-drug regimen of doravirine/islatravir (DOR/ISL) in adults with HIV-1 infection.

The trials included patients who were virologically suppressed on different antiretroviral therapy regimens, including antiretroviral therapy regimens [baseline antiretroviral therapy (bART) and Bictegravir/​Emtricitabine/​Tenofovir Alafenamide (BIC/​FTC/​TAF).

DOR/ISL was demonstrated to be non-inferior to bART in open-label trial MK-8591A-051 and non-inferior to BIC/FTC/TAF in double-blind trial MK-8591A-052.

Also Read: Gilead Sciences/Merck’s Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks

Trial MK-8591A-052 did not meet the superiority criteria, but both trials also met the primary safety objectives.

The company plans to present detailed findings from these trials at a future scientific congress and file the data with regulatory authorities.

In the U.S., doravirine is approved for the treatment of adults with HIV-1 in combination with other antiretrovirals, as a single agent (PIFELTRO) and a component of a single-tablet regimen [DELSTRIGO; doravirine, lamivudine, and tenofovir disoproxil fumarate (DOR/3TC/TDF)].

Islatravir (MK-8591), Merck’s investigational drug, is being evaluated in multiple early and late-stage clinical trials in combination with other antiretroviral therapies for the treatment of HIV-1.

In addition to the MK-8591A-051 and MK-8591A-052 trials, ongoing Phase 3 trials of DOR/ISL include MK-8591A-053 in people with HIV who had not previously received treatment (treatment-naïve) and MK-8591A-054 evaluating open-label DOR/ISL in individuals who participated in earlier Phase 3 trials of DOR/ISL.

Price Action: MRK stock is up 1.18% at $99.50 at last check Thursday.

Also Read:

Photo: HIV/AIDS ribbon via Shutterstock.

MRK Logo
MRKMerck & Co Inc
$83.044.01%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum
17.33
Growth
98.07
Quality
74.34
Value
19.18
Price Trend
Short
Medium
Long
Got Questions? Ask
Which biotech firms may benefit from Merck's results?
How will HIV treatment landscape shift post-trials?
Could investors capitalize on Merck's pipeline?
What impact on antiretroviral stocks from Merck's findings?
Which pharmaceutical stocks are vulnerable to DOR/ISL?
How might clinical trial successes influence market trends?
Who stands to gain from HIV drug advancements?
What are the long-term prospects for Merck's stock?
How will competition respond to DOR/ISL results?
Which investments might be undervalued in the HIV sector?
Market News and Data brought to you by Benzinga APIs

Posted In:
Comments
Loading...